SPM
NTLA icon

Symmetry Peak Management’s Intellia Therapeutics NTLA Stock Holding History

Symmetry Peak Management’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-9,500
Closed -$200K – 96
2020
Q2 		$200K Buy
+9,500
New +$161K 0.16% 74

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Chevy Chase Trust
Chevy Chase Trust Bethesda, Maryland $34.7B AUM 29.45% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Symmetry Peak Management's NTLA Position: Q3 2020 in Review

Symmetry Peak Management sold out of Intellia Therapeutics (NTLA) in Q3 2020, closing a stake of 9,500 shares — an estimated $200K sold.

Symmetry Peak Management first reported a position in NTLA in Q2 2020 and held it in 1 quarter. The position peaked at $200K in Q2 2020. 165 funds tracked by Wall St. Rank hold NTLA as of Q3 2020.

  • Symmetry Peak Management reported no remaining Intellia Therapeutics position as of Q3 2020 after selling out during the quarter.
  • Symmetry Peak Management sold 9,500 Intellia Therapeutics shares in Q3 2020, an estimated $200K.
  • Symmetry Peak Management first reported a position in Intellia Therapeutics in Q2 2020 and held it in 1 quarter.
  • Symmetry Peak Management's Intellia Therapeutics position peaked at $200K in Q2 2020.
  • 165 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q3 2020.

Based on Symmetry Peak Management's 13F filing for Q3 2020, filed 16 Nov 2020.